Programme | BioRN

BioRN Annual Conference 2019 - 11 November

Date and location:

11 November, 09:30 am

German Cancer Research Center, Heidelberg

Deadlines:

Registration - 6 November

Abstracts and Posters - early submission July 31

- late submission September 15

Programme

09:30 - 10:00

Registration & Get-together

10:00 - 10:30

Welcome

Gitte Neubauer - Cellzome, a GSK Company and BioRN Executive Board

Michael Boutros - German Cancer Research Center (DKFZ) and BioRN Executive Board

Theresia Bauer - Minister of Science, Research and the Arts, Member of the State Government of Baden-Württemberg

10:30 - 11:00

Keynote - The resolution revolution and the consequences for Heidelberg

Stefan Hell - Max Planck Institute for Medical Research, Heidelberg and Max Planck Institute for Biophysical Chemistry, Göttingen

11:00 - 11:20

Computational single-cell genomics - advances and translational opportunities

Oliver Stegle - German Cancer Research Center (DKFZ) and European Molecular Biology Laboratory (EMBL)

11:20 - 11:40

Machine Learning in Computer-aided Drug Design

Rebecca Wade - Heidelberg Institute for Theoretical Studies (HITS) and Heidelberg University

11:40 - 12:30

Research Short-Talks: project pitching by PhD Students and Postdoctoral Fellows

12:30 - 14:00

Lunch & Networking & Industry Poster Exhibition

14:00 - 14:40

HAEP - A Novel Format to Foster Academia-Industry Partnerships
Friedemann Loos, BioRN

HAEP Success Stories:

Closing the gap between “episteme” and “techne”: challenges for successful biotechnology transfer Patrick Most - University Hospital Heidelberg, Jefferson University and AaviGen GmbH
Artificial Intelligence: Deep Learning in Medicine, Myth or Reality? Sergey Biniaminov - HS Analysis
Organs-On-A-Chip And Artificial Intelligence Platforms In Personalized Medication Development - Ute Schepers - Karlsruhe Institute of Technology (KIT) and VasQlab

14:40 - 15:00

opnMe.com, a digital platform for sharing chemical tools

Adrian Carter - Boehringer Ingelheim

15:00 - 15:20

Value and Challenges of Data-Explosion in Pharma R&D

Lars Greiffenberg - AbbVie

15:20 - 15:40

Artificial Intelligence - Benchmarking research in the Rhein-Neckar Region and implications for Life Science Players

Maria de Kleijn - Elsevier

15:40 - 16:00

AI in Drug Discovery at Merck: benefits and perspectives

Friedrich Rippmann - Merck